Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Regulation of Hematopoietic Stem Cells01:01

Regulation of Hematopoietic Stem Cells

3.6K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.6K
Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

3.7K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
3.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ayush Bala Rakshak Leham for Moderate Malnutrition in Children Aged 3 to 5 Years: Protocol for a Pilot Randomized Controlled Trial.

JMIR research protocols·2026
Same author

High-Rate Fingerprinting of Protein Isoforms by Quasi-regulated Enzyme-free Transport Through CytK Nanopores.

Research square·2026
Same author

Role of Hybrid Fixator in Proximal Tibial Fractures: A Prospective Evaluation of Clinical and Radiological Outcomes.

Cureus·2026
Same author

Association of Proteinuria With Disease Stage and Treatment Response in Patients With Lymphoma: A Prospective Cohort Study.

Cureus·2026
Same author

Comprehensive Safety Evaluation of Ekangveer Rasa: A Herbo-Metallic Ayurvedic Formulation in Wistar Rats Following Acute and Sub-Chronic Oral Administration.

Biological trace element research·2026
Same author

`Effect of adjunctive antimicrobial photodynamic therapy on periapical healing and IL-6 modulation in apical periodontitis: a pilot randomized controlled study.

Lasers in medical science·2026

Related Experiment Video

Updated: Nov 25, 2025

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells
10:21

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells

Published on: February 21, 2018

10.2K

Development of Site-Specific PEGylated Granulocyte Colony Stimulating Factor With Prolonged Biological Activity.

Monika Kumari1, Girish Sahni1, Sonal Datta1

  • 1Council of Scientific and Industrial Research, Institute of Microbial Technology, Chandigarh, India.

Frontiers in Bioengineering and Biotechnology
|December 17, 2020
PubMed
Summary

Engineered cysteine variants of human granulocyte colony stimulating factor (huG-CSF) offer improved, site-specific PEGylation. These new variants demonstrate longer-lasting therapeutic effects and enable same-day administration for neutropenia treatment.

Keywords:
G-CSFPEGylated G-CSFcancer chemotherapyneutropeniaprolonged biological activity of G-CSFsite-specific PEGylation

More Related Videos

Isolation of Exosome-Enriched Extracellular Vesicles Carrying Granulocyte-Macrophage Colony-Stimulating Factor from Embryonic Stem Cells
12:02

Isolation of Exosome-Enriched Extracellular Vesicles Carrying Granulocyte-Macrophage Colony-Stimulating Factor from Embryonic Stem Cells

Published on: November 11, 2021

4.4K
A Cell Free Assay System Estimating the Neutralizing Capacity of GM-CSF Antibody using Recombinant Soluble GM-CSF Receptor
07:45

A Cell Free Assay System Estimating the Neutralizing Capacity of GM-CSF Antibody using Recombinant Soluble GM-CSF Receptor

Published on: June 27, 2011

12.9K

Related Experiment Videos

Last Updated: Nov 25, 2025

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells
10:21

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells

Published on: February 21, 2018

10.2K
Isolation of Exosome-Enriched Extracellular Vesicles Carrying Granulocyte-Macrophage Colony-Stimulating Factor from Embryonic Stem Cells
12:02

Isolation of Exosome-Enriched Extracellular Vesicles Carrying Granulocyte-Macrophage Colony-Stimulating Factor from Embryonic Stem Cells

Published on: November 11, 2021

4.4K
A Cell Free Assay System Estimating the Neutralizing Capacity of GM-CSF Antibody using Recombinant Soluble GM-CSF Receptor
07:45

A Cell Free Assay System Estimating the Neutralizing Capacity of GM-CSF Antibody using Recombinant Soluble GM-CSF Receptor

Published on: June 27, 2011

12.9K

Area of Science:

  • Biotechnology
  • Pharmacology
  • Protein Engineering

Background:

  • Current amino-terminal PEGylated human granulocyte colony stimulating factor (huG-CSF) has limitations including non-specific PEGylation and short duration of action.
  • Existing huG-CSF treatments cannot be administered on the same day as chemotherapy due to potential adverse effects.

Purpose of the Study:

  • To engineer novel huG-CSF variants with improved therapeutic potential through site-specific PEGylation.
  • To overcome the drawbacks of current huG-CSF treatments, enabling longer action and same-day administration.

Main Methods:

  • Engineered cysteine variants of huG-CSF for maleimide-based site-specific PEGylation.
  • Utilized varying molecular weights of PEG (20 kDa, 30 kDa, 40 kDa) for conjugation.
  • Evaluated leukocyte proliferative activity and therapeutic efficacy in neutropenic mouse models.

Main Results:

  • Site-specific PEGylation resulted in a highly homogenous product with comparable activity to commercial huG-CSF.
  • Higher molecular weight PEGylation (30 kDa and 40 kDa) significantly prolonged leukocyte proliferation activity.
  • A half-dose of 40 kDa PEGylated huG-CSF variant showed longer biological activity than commercial 20 kDa PEGylated huG-CSF.
  • The engineered variant demonstrated efficacy in alleviating neutropenia when administered on the same day as chemotherapy induction.

Conclusions:

  • Developed site-specific PEGylated huG-CSF variants with enhanced therapeutic properties.
  • These variants offer potential for long-acting and same-day prophylactic administration of G-CSF.
  • The findings pave the way for new G-CSF derivatives with extended half-lives and improved clinical attributes.